Orbactiv Launch Strategy Will Focus On Savings From Avoiding Hospitalization
This article was originally published in The Pink Sheet Daily
Executive Summary
The novel antibiotic will fit well into a treatment paradigm moving more toward outpatient care, The Medicines Co. execs explained to investors. The firm will stress cost savings, reduced need for hospitalization and a virtual guarantee of patient compliance.
You may also be interested in...
Durata Plans To Pitch Dalbavancin As Cost-Saving Paradigm Changer
Company plans to file an NDA for the antibiotic in September, built partly on clinical work done by the drug’s previous owner, Pfizer. Given hospitals’ emphasis on cost, Durata’s marketing plan will highlight the drug’s two-dose regimen, which could help move treatment to the ambulatory-care setting.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.